Clinical Trial Finder

Inclusion Criteria:

• - Age: > or = 18 years old.

• - Rotator Cuff Tendinitis.

• - Atraumatic Full-thickness Rotator Cuff Tear.

• - Subjects who speak English.

• - Women who are of non-childbearing potential.

Exclusion Criteria:

• - Age: < 18 years old.

• - Prior Shoulder Surgery.

• - Fracture.

• - Acute Traumatic Rotator Cuff Tear.

• - Infection.

• - Uncontrolled Diabetes Mellitus (HbA1c >8) - Uncontrolled High Blood Pressure (Hypertension) - Recent Prior Shoulder Injection in either the Subacromial space Workers Compensation.

• - History of Peptic Ulcer disease (includes both Gastric and Duodenal Ulcers), Gastrointestinal perforation, Inflammatory Bowel disease (Ulcerative Colitis, Crohn's disease), or any other gastrointestinal pathology.

• - Tumor Involving the Shoulder Region.

• - Prior history of gastrointestinal bleeding, allergic reactions, impaired renal function, seizures or cardiac arrhythmias.

• - Subject unable to provide informed consent.

• - Subjects who don't speak English.

• - Patients who are pregnant or lactating at time of screening or are of pregnant bearing age.

• - Patients currently receiving an aspirin, NSAID regimen or any other anti-inflammatory agents that could affect inflammation response.

• - Patients taking any anti-platelet agents, warfarin or other anticoagulants, or SSRIs.

• - Patients with any bleeding disorders such as coagulopathy, hypercoagulable state, or platelet disorders including thrombocytopenia.

• - Patients with cardiac disease such as congestive heart failure, coronary artery disease, or myocardial infarction.

• - Patients with severe renal failure.

Patients with severe liver impairment or active liver disease.

• - Patients with heavy alcohol use; this is defined as consuming 8 or more drinks per week for a woman and 15 or more drinks per week for a man.

• - Patients likely to have severe problems maintaining follow-up, including patients diagnosed with severe psychiatric conditions, patients who live too far outside the hospital's catchment area, patients who are incarcerated and patients who have unstable housing situations.

Patients with a known hypersensitivity to bupivacaine or other local anesthetic agent of the amide-type.

• - Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.

• - Patients who are allergic to aspirin, ketorolac tromethamine and other NSAIDs.

• - Patients who are currently on probenecid or pentoxifylline as described in the approved label of Ketorolac tromethamine injection.

The proposed study is a three arm, double-blinded, prospective randomized controlled clinical trial with follow-up immediately after the injection and at day 2, and weeks 1, 2, 4, 6, and 12. In this study investigators will compare the effectiveness of ketorolac compared to corticosteroid. Subjects being seen for a rotator cuff injury will be randomized into one of three treatment groups pertaining to their pathology. The intervention will begin once the subject has consented and answered the Baseline Outcome Shoulder Questionnaire. The Baseline Outcome Questionnaire consists of the Visual Analog Score, American Shoulder and Elbow Score, Single Assessment Numeric Evaluation, Pittsburgh Sleep Quality Index, Short Form-12, and questions pertaining to patient characteristics, injury characteristics, co-morbidities, patient history, medications, and demographics.

Arms

Other: Group 1 (marcaine)

will receive an injection of 4 cc 0.25% Marcaine without epinephrine

Experimental: Group 2 (ketorolac)

will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1

Other: Group 3 (kenalog)

4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1. Group 3 is standard of care

Interventions

Drug: - Ketorolac

Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1

Drug: - Marcaine

Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine

Drug: - Kenalog

Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.